71 / 74 · 0:58 · Original AXON film
PS T2
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
PS T2 | Identity unresolved
PS T2 is a code, and a code alone cannot establish chemical identity. The material behind this catalog label has not been independently verified here. [1]
Identity requires traceable evidence
Scientific interpretation begins with a defined substance, its manufacturer and batch, and analytical evidence linking the tested sample to that identity. Similar names are insufficient. [1] [2]
Identity and purity are separate questions
Official manufacturing guidance treats identity and purity as distinct quality questions. A purity percentage, without an appropriate identification method, does not answer what a sample contains. [1] [2]
No inferred molecule or treatment claim
Until the identity is resolved, attaching another compound's benefits or risks would be speculative. This topic remains an identification question, not an efficacy claim. [1] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- FDA: Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients →General principles of identity testing, traceable batches and quality; does not identify PS T2.
- FDA (2024): Q2(R2) Validation of Analytical Procedures →General method-validation framework; no evidence for PS T2 identity or efficacy.
